SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 9, 2020

OptimizeRx Corporation
(Exact name of registrant as specified in its charter)

 

Nevada   001-38543   26-1265381
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

400 Water Street, Suite 200, Rochester, MI   48307
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 248.651.6568

 

 

___________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock   OPRX   Nasdaq Capital Market

 

 

 

 

SECTION 8 – Other Events

 

Item 8.01 Other Events

 

On September 9, 2020, we issued a press release announcing our invitation to participate in two investor conferences being held in September. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

SECTION 9 – Financial Statements and Exhibits

 

Item 9.01 Financial Statements and Exhibits

 

99.1 Press release, dated September 9, 2020

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

OptimizeRx Corporation

 

/s/ Douglas Baker      
Douglas Baker      
Chief Financial Officer      

 

Date: September 9, 2020

 

 

2

 

Exhibit 99.1

 

 

 


OptimizeRx to Participate at Investor Conferences in September

ROCHESTER, Mich. – September 9, 2020 – OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, providers and patients, has been invited to participate in two investor conferences being held in September.

 

Event: H.C. Wainwright’s 22nd Annual Global Investment Conference

Date: September 14-16, 2020

Format: 1x1 meetings and live company presentation

Webcast date and time: September 16th at 1:00 p.m. EDT

Webcast link: click here

Please contact your H.C. Wainwright institutional sales representative for registration information.

 

Event: Lake Street Capital Markets’ 4th Annual Best Ideas Growth (BIG4) Conference

Date: September 17, 2020

Format: 1x1 meetings

Please contact your Lake Street institutional sales representative for registration information.

 

OptimizeRx management is scheduled to participate in virtual one-on-one meetings with institutional investors and analysts at both conferences.

 

Management will discuss how OptimizeRx’s growing digital point-of-care solutions have evolved into ‘must-haves’ for life science companies looking to improve essential communications with physicians and patients.

 

They will also discuss the company’s recent expansion of its digital health platform from ambulatory and acute care to retail pharmacy, which includes access to a new nationwide network of 10,000 FDA-cleared self-screening Smart Health Stations.

 

To schedule a virtual one-on-one meeting with OptimizeRx, you may submit your request via the links provided upon your registration for the conferences. For any questions about OptimizeRx, please contact Ron Both of CMA at (949) 432-7557 or submit your request here.

 

About H.C. Wainwright

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions.  H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information about H.C. Wainwright, visit www.hcwco.com.

 

 

 

About Lake Street Capital Markets

Lake Street Capital Markets is a research-powered investment bank focused on select, high-growth companies and sectors of the economy. Their research enables institutional investors to understand emerging secular trends and identify innovative companies best positioned to capitalize on them. Lake Street provides companies with access to capital and helps build relationships to drive long-term growth. At the core of everything it does is their commitment to providing informed advice and exceptional service to its clients. For more information about Lake Street, visit www.lakestreetcapitalmarkets.com.

 

About OptimizeRx

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence and care management. OptimizeRx’s network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support on specialty medications and patient financial assistance directly within a provider’s workflow through leading electronic health platforms. OptimizeRx’s fully integrated platform supports the real-time exchange of information, improving provider knowledge and patient engagement, and ultimately leading to healthier outcomes.

For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. 

 

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. 

 

OptimizeRx Contact 

Doug Baker, CFO

Tel (248) 651-6568 (x807)

dbaker@optimizerx.com 

 

Media Relations Contact 

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070

malejandra@optimizerx.com

 

Investor Relations Contact 

Ron Both, CMA 

Tel (949) 432-7557 

oprx@cma.team